Bristol-Myers Squibb is going after a second indication for its first-to-market cardiac myosin inhibitor Camzyos, a drug tipped to be a future blockbuster and the top prospect in the compan
Roche's third-quarter results have revealed a clear sign that the bumper sales boosting companies that have provided products to diagnose, treat or prevent COVID-19 since the start of the p
Precision medicine is oft spoken about these days, as it is finally addressing the elephant in the room: one size – or, more appropriately, one dose – does not fit all.